지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 204 - 208 (5page)
이용수
초록· 키워드
오류제보하기
Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea. We report a 72 year-old man patient with polycythemia vera who developed multiple cutaneous squamous cell carcinomas (cSCCs) with keratoacanthoma-like histological features while on treatment with ruxolitinib. Similar lesions have been reported in an isolated patient who also received ruxolitinib. Our case confirms that ruxolitinib may induce eruptive cSCCs with characteristic clinical and histological features that differentiate them from conventional non-drug induced lesions. Moreover, we performed a mutational panel analysis of the tumors. The lack of specific mutations in these tumors suggests an impairment of immunosurveillance in the origin of the cutaneous lesions. Frequent and thorough dermatological examinations in patients receiving ruxolitinib with a history of photodamage, skin cancer and/or previous hydroxyurea intake is thus recommended.
목차
등록된 정보가 없습니다.
참고문헌 (19)
참고문헌 신청
Rane SG / 2002 / JAKs, STATs and Src kinases in hematopoiesis / Oncogene 21:3334~3358
Jatiani SS / 2010 / Jak/STAT pathways in cytokine signaling and myeloproliferative disorders : approaches for targeted therapies / Genes Cancer 1:979~993
Deisseroth A / 2012 / Food and Drug Administration approval : ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis / Clin Cancer Res 18:3212~3217
Caocci G / 2014 / Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis / Leukemia 28:225~227
Goldberg RA / 2013 / Bilateral toxoplasmosis retinitis associated with ruxolitinib / N Engl J Med 369:681~683
Jatiani SS / 2010 / Jak/STAT pathways in cytokine signaling and myeloproliferative disorders : approaches for targeted therapies / Genes Cancer 1:979~993
Deisseroth A / 2012 / Food and Drug Administration approval : ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis / Clin Cancer Res 18:3212~3217
Caocci G / 2014 / Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis / Leukemia 28:225~227
Goldberg RA / 2013 / Bilateral toxoplasmosis retinitis associated with ruxolitinib / N Engl J Med 369:681~683
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Ruxolitinib and Severe COVID-19
Infection and Chemotherapy
2021 .12
-
Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis
Infection and Chemotherapy
2021 .09
-
Real-life ruxolitinib experience in intermediate-risk myelofibrosis
Blood Research
2021 .12
-
Ruxolitinib-induced extreme thrombocytosis in a COVID-19 patient
Blood Research
2021 .09
-
단일 기관 내 Steroid-Refractory Graft-versus-Host Disease 환자에서의 Ruxolitinib 반응성 평가
병원약사회지
2023 .05
-
A Pediatric Case of Atypical Chronic Myeloid Leukemia with CSF3R Mutation Not Responding to Ruxolitinib, but Rescued by Allogeneic Transplantation
Clinical Pediatric Hematology-Oncology
2021 .10
-
Novel therapeutics for myelofibrosis
Blood Research
2023 .04
-
The Tumor Immune Microenvironment in Cutaneous Squamous Cell Carcinoma Arising in Organ Transplant Recipients
Annals of Dermatology
2023 .04
-
골수증식종양의 치료제인 하이드록시유레아의 부작용
대한의사협회지
2023 .04
-
진성적혈구증가증/본태성혈소판증가증 치료의 발전
대한내과학회지
2016 .01
-
Treatment with ropeginterferon alfa-2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea: one-year results from a phase 2 study
Blood Research
2024 .09
-
Cutaneous Spindle Cell Squamous Cell Carcinoma
Annals of Dermatology
2015 .01
-
Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
Blood Research
2021 .12
-
Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
JAK-2 V617F Mutational Analysis in Primary Idiopathic Myelofibrosis: Experience from Southern Pakistan
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
적혈구증가증의 감별진단
대한내과학회지
2020 .02
-
Clinical Features of Cutaneous Premalignant Lesions in Busan City and the Eastern Gyeongnam Province, Korea: A Retrospective Review of 1,292 Cases over 19 Years (1995∼2013)
Annals of Dermatology
2016 .01
-
P16<sup>INK4a</sup> Immunostaining but Lack of Human Papilloma Virus Type 16 in Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma: a Report from West Iran
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Cutaneous Basal Cell Carcinoma Arising in Odontogenic Cutaneous Fistula
Archives of craniofacial surgery : ACFS
2017 .01
-
Differences in Clinical Outcomes Between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients
Journal of Korean Medical Science
2024 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0